Importance of optimal dosing ≥30mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia

Ali Taher, Mohsen S. Elalfy, Kusai Al Zir, Shahina Daar, Abdullah Al Jefri, Dany Habr, Ulrike Kriemler-Krahn, Ali El-Ali, Bernard Roubert, Amal El-Beshlawy

Research output: Contribution to journalArticle

24 Citations (Scopus)


Following 1-yr deferasirox therapy in the ESCALATOR study, 57% of previously chelated patients with β-thalassaemia achieved treatment success (maintenance of or reduction in liver iron concentration (LIC) vs. baseline LIC). Seventy-eight per cent had dose increases at median of 26wk, suggesting that 1-yr results may not have reflected full deferasirox efficacy. Extension data are presented here. Deferasirox starting dose was 20mg/kg/d (increases to 30/40mg/kg/d permitted in the core/extension, respectively). Efficacy was primarily assessed by absolute change in LIC and serum ferritin. Overall, 231 patients received deferasirox in the extension; 67.4% (P

Original languageEnglish
Pages (from-to)355-365
Number of pages11
JournalEuropean Journal of Haematology
Issue number4
Publication statusPublished - Oct 2011



  • β-thalassaemia
  • Deferasirox
  • Efficacy
  • Iron chelation therapy
  • Iron overload

ASJC Scopus subject areas

  • Hematology

Cite this